Amid concerns that patent reviewers disregard competitive effects on prescription drugs, a bipartisan group of senators introduced a bill to require the Food and Drug Administration and the Patent & Trademark Office to create a task force to boost coordination.
The goal is for the agencies to share information about their respective review procedures, improve communication about scientific trends, make it possible to swap confidential information, and determine whether pharmaceutical companies are providing accurate representations about their products.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
